ALTAltimmune Inc

Earlier on Tuesday, Altimmune said the mid-stage RECLAIM trial met its main goal and key secondary goals.

Altimmune’s Phase 2 trial showed Pemvidutide reduced heavy drinking by 4.20 days per week compared with the placebo’s 2.75 days.

Altimmune (NASDAQ:ALT) delivered one of its most significant clinical milestones to date, reporting positive topline results from its RECLAIM Phase 2 trial evaluating pemvidutide in patients with moderate to severe alcohol use disorder (AUD). The investigational dual glucagon/GLP-1 receptor agonist met the study's primary endpoint, producing a statistically significant reduction in heavy drinking days compared with placebo while also achieving multiple important secondary endpoints recognized by the U.S. Food and Drug Administration (FDA) as potential registrational measures.

Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market...

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.